IMM01
- Generic Name
- IMM01
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
IMM01 is a recombinant human signal regulatory protein α (SIRPα) IgG 1 fusion protein. IMM01 is under investigation in clinical trial NCT05140811 (A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome).
- Associated Conditions
- -
- Associated Therapies
- -
IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)
- Conditions
- Interventions
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Target Recruit Count
- 170
- Registration Number
- NCT06647862
- Locations
- 🇨🇳
Zhujiang Hospital of Southern Medical University, Zhujiang, Guangdong, China
🇨🇳Guangdong Provincial People's Hospital, Guangzhou, Guangzhou, China
🇨🇳The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
Exploratory Study of IMM01 for Injection in the Treatment of Refractory or Recurrent Hematologic Malignancy
- First Posted Date
- 2023-05-16
- Last Posted Date
- 2023-05-16
- Lead Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Target Recruit Count
- 73
- Registration Number
- NCT05860075
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences and Peking Union Medical College,, Tianjin, Tianjin, China
Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2023-04-27
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Target Recruit Count
- 309
- Registration Number
- NCT05833984
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, China
🇨🇳Shandong Provincial Institute of Cancer Prevention and Treatment, Jinan, China
🇨🇳The Third Affiliated Hospital of Qiqihar Medical University, Qiqihar, China
A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2021-12-01
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Target Recruit Count
- 126
- Registration Number
- NCT05140811
- Locations
- 🇨🇳
The first affiliated hospital of nanchang University, Nanchang, China
🇨🇳Shanghai sixth's hospital, Shanghai, China
🇨🇳Ganzhou People's Hospital, Ganzhou, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.